title: The underutilization of intrathecal baclofen in poststroke spasticity.
abstract: Stroke is one of the leading causes of adult disability in the United States, with a reported prevalence of 6.4 million people. Spasticity is one of the clinical features of the upper motor neuron syndrome seen after a stroke. The prevalence of spasticity after a stroke ranges from 17% to 42.6%, and an average of two-thirds of people with spasticity have upper and lower extremity involvement. Oral medications and botulinum neurotoxin injections are current treatments for problematic spasticity. However, these treatments are often limited by side effects or dose ceilings. Intrathecal baclofen (ITB) is a proven method for the management of disabling spasticity from multiple etiologies. Studies have demonstrated improved mobility, activities of daily living, and quality of life in spastic poststroke patients. Despite the benefits of ITB, fewer than 1% of stroke patients with severe disabling spasticity are being treated with ITB. This article will review the prevalence of severe poststroke spasticity and the rate of ITB use and will discuss reasons for its limited use in stroke survivors.
authors.affiliation: Aurora Medical Center Summit, Summit, Wisconsin, USA.
authors.forename: Eric M
authors.initials: EM
authors.lastname: Dvorak
authors.forename: Nicholas C
authors.initials: NC
authors.lastname: Ketchum
authors.forename: John R
authors.initials: JR
authors.lastname: McGuire
mesh_terms: D001418:Baclofen / Q000008:administration & dosage*; D006801:Humans; D007278:Injections, Spinal / Q000379:methods; D009125:Muscle Relaxants, Central / Q000008:administration & dosage*; D009128:Muscle Spasticity / Q000188:drug therapy* / Q000209:etiology* / Q000523:psychology; D011788:Quality of Life; D020521:Stroke / Q000150:complications* / Q000453:epidemiology; D014481:United States / Q000453:epidemiology
chemical_list: D009125:Muscle Relaxants, Central; D001418:Baclofen